OKYO To Initiate Global Phase 3 NEPTUNE Trial In Neuropathic Eye Pain, Enrolling 111 Patients Across US And Europe In 2026 Following Positive FDA Feedback

Loading news article.

OKYO To Initiate Global Phase 3 NEPTUNE Trial In Neuropathic Eye Pain, Enrolling 111 Patients Across US And Europe In 2026 Following Positive FDA Feedback | WAPE

OKYO To Initiate Global Phase 3 NEPTUNE Trial In Neuropathic Eye Pain, Enrolling 111 Patients Across US And Europe In 2026 Following Positive FDA Feedback

Article summary

Related companies

Comments —